Economic model of albumin infusion in septic shock: The EMAISS study.
Bertrand GuidetIdir GhoutJacques RopersPhilippe AegerterPublished in: Acta anaesthesiologica Scandinavica (2020)
Based on the risk reduction observed in the septic shock subgroup analysis of the ALBIOS dataset, the application of the ALBIOS trial results to Cub-Réa data may suggest that albumin infusion is likely cost-effective in septic shock.